<DOC>
	<DOCNO>NCT00158678</DOCNO>
	<brief_summary>This multicentric randomized phase III trial compare intensity-modulated radiotherapy ( 75 Gy ) plus cisplatin versus conventional radiotherapy ( 70 Gy ) plus cisplatin patient stage III-IV squamous cell carcinoma oral cavity , oropharynx hypopharynx . The main end point rate locoregional control rate xerostomia 2 year .</brief_summary>
	<brief_title>IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin Stage III-IV HNSCC</brief_title>
	<detailed_description>This multicentric randomized phase III trial compare intensity-modulated radiotherapy plus concomitant cisplatin versus conventional radiotherapy plus concomitant cisplatin patient stage III-IV squamous cell carcinoma oral cavity , oropharynx hypopharynx . The main end point rate locoregional control rate xerostomia 2 year . The IMRT total dose 75 Gy ( 50 Gy PTV1 T0 + 25 Gy ( 10 fraction ) PTV2 ) . The conventional radiotherapy total dose 70 Gy ( 50 Gy PTV1 + 20 Gy ( 10 fraction ) PTV2 ) . In arm , cervical node receive 50 Gy ( 65 Gy case Np ) conventional radiotherapy ( IMRT allow IRMT arm ) . In two arm , patient receive concomitant cisplatin ( 100 mg/mÂ² D1 , D21 , D42 ) .</detailed_description>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Hypopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>squamous cell carcinoma oral cavity , oropharynx hypopharynx Stage III IV ( T1T4 , N0N2 ) ( UICC 2002 ) Not resect Indication radiotherapy bilateral cervical node dose &gt; = 50 Gy Delineation target volume do randomization Scintigraphy parotid gland do radiotherapy start Quality life questionnaire ( EORTCC30 EORTCH &amp; N35 ) fill patient Informed consent sign N3 ( UICC 2002 ) Distant metastasis Contraindication concomitant cisplatin History cancer within last 5 year History head neck radiotherapy Administration drug treatment prophylaxis xerostomia ( pilocarpine , ethyol )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>oral cancer</keyword>
	<keyword>oropharynx cancer</keyword>
	<keyword>hypopharynx cancer</keyword>
	<keyword>IMRT</keyword>
</DOC>